JP2018520654A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520654A5
JP2018520654A5 JP2017560946A JP2017560946A JP2018520654A5 JP 2018520654 A5 JP2018520654 A5 JP 2018520654A5 JP 2017560946 A JP2017560946 A JP 2017560946A JP 2017560946 A JP2017560946 A JP 2017560946A JP 2018520654 A5 JP2018520654 A5 JP 2018520654A5
Authority
JP
Japan
Prior art keywords
antibody
host cell
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560946A
Other languages
English (en)
Other versions
JP2018520654A (ja
JP6518917B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/034716 external-priority patent/WO2016196314A1/en
Publication of JP2018520654A publication Critical patent/JP2018520654A/ja
Publication of JP2018520654A5 publication Critical patent/JP2018520654A5/ja
Application granted granted Critical
Publication of JP6518917B2 publication Critical patent/JP6518917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (8)

  1. 配列番号41に記載のアミノ酸配列を含む重鎖および配列番号40に記載のアミノ酸配列を含む軽鎖を含む、抗CD40抗体。
  2. 請求項1に記載の抗CD40抗体および医薬として許容される担体を含む、医薬組成物。
  3. 請求項1に記載の抗CD40抗体アミノ酸配列をコードする、単離された核酸。
  4. 請求項に記載の単離された核酸を含む、ベクター。
  5. 請求項に記載のベクターを含む、宿主細胞。
  6. 原核細胞または真核細胞である、請求項に記載の宿主細胞。
  7. HO細胞またはCOS細胞である、請求項に記載の宿主細胞。
  8. 請求項1に記載の抗CD40抗体を産生する方法であって、請求項5から7のいずれか一項に記載の宿主細胞を、培養培地中、抗CD40抗体が産生されるのに十分な条件下で培養するステップを含む、方法。
JP2017560946A 2015-05-29 2016-05-27 抗cd40抗体およびその使用 Active JP6518917B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168425P 2015-05-29 2015-05-29
US62/168,425 2015-05-29
PCT/US2016/034716 WO2016196314A1 (en) 2015-05-29 2016-05-27 Anti-cd40 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019049426A Division JP6842488B2 (ja) 2015-05-29 2019-03-18 抗cd40抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2018520654A JP2018520654A (ja) 2018-08-02
JP2018520654A5 true JP2018520654A5 (ja) 2019-03-22
JP6518917B2 JP6518917B2 (ja) 2019-05-29

Family

ID=56118046

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017560946A Active JP6518917B2 (ja) 2015-05-29 2016-05-27 抗cd40抗体およびその使用
JP2019049426A Active JP6842488B2 (ja) 2015-05-29 2019-03-18 抗cd40抗体およびその使用
JP2021024919A Pending JP2021090433A (ja) 2015-05-29 2021-02-19 抗cd40抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019049426A Active JP6842488B2 (ja) 2015-05-29 2019-03-18 抗cd40抗体およびその使用
JP2021024919A Pending JP2021090433A (ja) 2015-05-29 2021-02-19 抗cd40抗体およびその使用

Country Status (35)

Country Link
US (3) US10174121B2 (ja)
EP (3) EP3626744A1 (ja)
JP (3) JP6518917B2 (ja)
KR (2) KR102661078B1 (ja)
CN (2) CN113603782A (ja)
AR (1) AR104809A1 (ja)
AU (2) AU2016270640B2 (ja)
BR (1) BR112017025693A2 (ja)
CA (1) CA2987051A1 (ja)
CL (1) CL2017003007A1 (ja)
CO (1) CO2017012286A2 (ja)
CR (1) CR20170592A (ja)
CY (1) CY1122593T1 (ja)
DK (1) DK3303395T3 (ja)
DO (1) DOP2017000273A (ja)
EC (1) ECSP17085333A (ja)
ES (1) ES2774016T3 (ja)
HK (1) HK1248718A1 (ja)
HR (1) HRP20200262T1 (ja)
HU (1) HUE048284T2 (ja)
IL (1) IL255961B (ja)
LT (1) LT3303395T (ja)
MX (1) MX2017015143A (ja)
PE (1) PE20180193A1 (ja)
PH (1) PH12017502161A1 (ja)
PL (1) PL3303395T3 (ja)
PT (1) PT3303395T (ja)
RS (1) RS59935B1 (ja)
RU (1) RU2715597C2 (ja)
SI (1) SI3303395T1 (ja)
TW (2) TWI688574B (ja)
UA (1) UA125208C2 (ja)
UY (1) UY36692A (ja)
WO (1) WO2016196314A1 (ja)
ZA (1) ZA201707903B (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957146A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
BR112017025693A2 (pt) * 2015-05-29 2018-08-14 Abbvie Inc. anticorpos anti-cd40 e seus usos
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
UA123111C2 (uk) * 2016-05-27 2021-02-17 Еббві Байотерапьютікс Інк. Антитіло до cd40 та його застосування
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
CA3064298A1 (en) 2017-06-01 2018-12-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
PE20201464A1 (es) * 2017-12-01 2020-12-17 Abbvie Inc Conjugados anticuerpo anti-cd40-farmaco
JP2021513367A (ja) * 2018-02-12 2021-05-27 ダイアベーツ−フリー, インコーポレイテッド 改善されたアンタゴニスト的抗ヒトcd40モノクローナル抗体
CN108918892B (zh) * 2018-08-01 2021-04-27 百奥泰生物制药股份有限公司 一种测定抗vegf抗体活性的方法及其应用
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
US20220025060A1 (en) 2018-11-30 2022-01-27 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereof
US20240254248A1 (en) 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
BR112021013174A2 (pt) 2019-01-11 2021-11-03 Novartis Ag Anticorpos anti-cd40 para uso no tratamento da hidradenite supurativa
US11110149B2 (en) 2019-02-20 2021-09-07 Ksl Biomedical Inc. Method for predicting and monitoring the efficacy of low-dose IL-2 and hydroxychloroquine therapy in autoimmune diseases and its long-term use in autoimmune-related conditions
CN109678959B (zh) * 2019-02-22 2020-12-08 北京免疫方舟医药科技有限公司 抗cd40抗体及其应用
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20220378907A1 (en) * 2019-11-13 2022-12-01 Children's Hospital Medical Center Methods for treating diseases
CN115052625A (zh) * 2019-12-03 2022-09-13 埃沃特克国际有限责任公司 干扰素相关抗原结合蛋白及其用途
CN115175919A (zh) * 2019-12-09 2022-10-11 光行科技株式会社 转换结合剂、其制备方法、和各自使用该转换结合剂的药物组合物、测定试剂盒、以及抗原和抗体测定方法
IL293640A (en) * 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
WO2022002065A1 (zh) * 2020-06-30 2022-01-06 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2022036495A1 (en) * 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
CN113341161A (zh) * 2021-06-10 2021-09-03 苏州大学附属第一医院 Icos/icosl在诊治变态反应性皮肤病中的应用
CN115768477A (zh) * 2021-06-29 2023-03-07 舒泰神(北京)生物制药股份有限公司 特异性识别cd40的抗体及其应用
JP2024525769A (ja) * 2021-07-14 2024-07-12 舒泰神(北京)生物製薬股フン有限公司 Cd40を特異的に認識する抗体およびその使用
CN114158523A (zh) * 2021-08-12 2022-03-11 昆明医科大学 一种改良兔腹主动脉粥样斑块模型的建立方法
CA3232304A1 (en) * 2021-09-26 2023-03-30 Chen SHEN Use of anti-cd40 antibody
WO2023230526A2 (en) * 2022-05-27 2023-11-30 Eledon Pharmaceuticals Methods for the treatment of kidney diseases or disorders
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
CN117777306B (zh) * 2023-07-04 2024-08-20 深圳豪石生物科技有限公司 一种靶向cldn18.2的增强型嵌合抗原受体及其用途
CN117777307B (zh) * 2023-09-26 2024-08-20 深圳豪石生物科技有限公司 一种cldn18.2特异性嵌合t细胞受体、嵌合t细胞受体免疫细胞及其应用
CN116990528B (zh) * 2023-09-27 2024-02-06 成都华西海圻医药科技有限公司 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780A (en) 1848-09-19 Improvement in preparing shoe-pegs
US4526A (en) 1846-05-16 Improvement in the mode o
US225A (en) 1837-06-03 Machine fob
US938A (en) 1838-09-22 Improvement in paddle-wheels for propelling boats
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
DE3590766T (ja) 1985-03-30 1987-04-23
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US5247069A (en) 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
ES2315612T3 (es) 1991-04-10 2009-04-01 The Scripps Research Institute Genotecas de receptores heterodimericos usando fagemidos.
ES2181673T3 (es) 1991-05-01 2003-03-01 Jackson H M Found Military Med Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
DK0724456T3 (da) 1993-10-01 2004-04-13 Immunex Corp CD40-Antistoffer
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ATE267607T1 (de) 1993-12-23 2004-06-15 Immunex Corp Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996033266A1 (en) 1995-04-21 1996-10-24 Cell Genesys, Inc. Generation of large genomic dna deletions
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
PT885002E (pt) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materiais e métodos para aumento da internalização celular
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
DE69835143T2 (de) 1997-01-21 2007-06-06 The General Hospital Corp., Boston Selektion von proteinen mittels rns-protein fusionen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
KR20010034554A (ko) 1998-03-03 2001-04-25 레이몬드, 엠. 위티 치료제로서의 cd147 결합 분자
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
TR200501367T2 (tr) 1999-03-25 2005-09-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
IL129907A (en) 1999-05-12 2006-08-01 Compugen Ltd Alternative splice variants
IL130989A0 (en) 1999-07-20 2001-01-28 Compugen Ltd Variants of alternative splicing
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
WO2002000879A2 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
AU2001296507A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
KR100923514B1 (ko) 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
EP2011802A3 (en) * 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
JP4025881B2 (ja) * 2001-04-27 2007-12-26 キリンファーマ株式会社 抗cd40モノクローナル抗体
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
CA2462113C (en) 2001-10-01 2013-01-29 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040028687A1 (en) 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
AU2003206045A1 (en) 2002-02-22 2003-09-09 Compugen Ltd. CD40 splice variants, method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
MXPA05009429A (es) 2003-03-05 2005-12-12 Halozyme Inc Glicoproteina hialuronidasa soluble (shasegp), proceso para preparar la misma, usos y composiciones farmaceuticas que la comprenden.
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
NZ548325A (en) * 2003-12-25 2009-07-31 Kirin Pharma Kk Mutants of anti-CD40 antibody
US20050281815A1 (en) 2004-02-26 2005-12-22 Dani Eshel CD40 splice variants and their uses
WO2005105840A2 (en) 2004-03-26 2005-11-10 Five Prime Therapeutics, Inc. Cd40 variants and uses thereof
WO2005100584A2 (en) 2004-04-15 2005-10-27 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US20070292439A1 (en) 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
AU2005294214A1 (en) 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
EP2468881A3 (en) 2005-07-21 2012-08-15 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007053767A1 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
CN101351478A (zh) 2005-11-01 2009-01-21 诺华有限公司 抗cd40抗体的应用
CN101426817B (zh) * 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
US20090285757A1 (en) 2008-05-16 2009-11-19 Northeastern University Methods of targeting cells for diagnosis and therapy
EP2406286B1 (en) * 2009-03-10 2016-05-18 Baylor Research Institute Anti-cd40 antibodies and uses thereof
US20110217363A1 (en) 2010-03-05 2011-09-08 Bionanox Two-step targeted tumor therapy with prodrug encapsulated in nanocarrier
HUE038788T2 (hu) * 2010-03-31 2018-11-28 Boehringer Ingelheim Int Anti-CD40 antitestek
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
AU2012229236B2 (en) 2011-03-11 2017-05-18 Beth Israel Deaconess Medical Center, Inc. Anti-CD40 antibodies and uses thereof
MX354243B (es) 2011-04-21 2018-02-20 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40.
EP3508500A1 (en) 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40 antibodies and methods of use
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
BR112017025693A2 (pt) * 2015-05-29 2018-08-14 Abbvie Inc. anticorpos anti-cd40 e seus usos
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2018520654A5 (ja)
HRP20200262T1 (hr) Protutijela protiv cd40 i njihova upotreba
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
CA3062698A1 (en) Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
MY189819A (en) Genetically modified cells and uses thereof
FI3390442T3 (fi) Anti-C5-vasta-aineita ja käyttömenetelmiä
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
WO2015051199A3 (en) Modified pseudomonas exotoxin a
WO2016011210A3 (en) Engineered cells for adoptive cell therapy
NZ723328A (en) Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
WO2015052350A3 (en) Live attenuated vaccines
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
AR092712A1 (es) Una proteina con actividad cetosa 3-epimerasa
SG10201909180SA (en) Humanized anti-c1s antibodies and methods of use thereof
AR083354A1 (es) Polipeptidos variantes cbh i (celobiohidrolasas i) con reducida inhibicion de producto
JP2016500260A5 (ja)
JP2018507204A5 (ja)
RU2017142878A (ru) Микроорганизм рода Escherichia, обладающий продуктивностью по L-триптофану, и способ получения L-триптофана с его использованием
RU2016147962A (ru) Микроорганизм, обладающий улучшенной способностью к продуцированию l-лизина, и способ производства l-лизина с использованием данного микроорганизма
AR102410A1 (es) Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
RU2017141773A (ru) Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ получения L-триптофана с его использованием
RU2016152662A (ru) Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ продуцирования L-триптофана с использованием данного микроорганизма